Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317767 | 0.91 | MAOB (0.56) | MAOBL3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7858163 | 0.87 | SMPD1 (0.51) | MAOBSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL7860259 | 0.84 | KMT2A (0.57) | ALDH1A1SMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL4441716 | 0.83 | MAOB (0.53) | MAOBSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL3191667 | 0.81 | MAOB (0.58) | MAOBL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL131382 | 0.80 | MAOB (0.55) | MAOBL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29717104 | 0.79 | MAOB (0.55) | MAOBL3MBTL1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL711327 | 0.79 | MAOB (0.55) | MAOBL3MBTL1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3962253 | 0.78 | MAOB (0.61) | MAOBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17386321 | 0.78 | L3MBTL1 (0.47) | MAOBL3MBTL1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2364700-B1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS INC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2545913-A1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2543371-A1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2543367-A1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2517702-A1 | Compounds, compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2364700-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2025058-A2 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | Paloma Pharmaceuticals, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133249-A2 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | MAOB 946/4885L3MBTL1 4456/4885ALDH1A1 2351/4885 |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | MAOB 946/4885L3MBTL1 4456/4885ALDH1A1 2351/4885 |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, FLT1 | MAOB 1462/4885L3MBTL1 2486/4885ALDH1A1 1226/4885 |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, HDGF | MAOB 1365/4885L3MBTL1 2478/4885ALDH1A1 1225/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | MAOB 946/4885L3MBTL1 4456/4885ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.